Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01493219 · ClinicalTrials.gov registry record

Biomarkers for Prognosis of Glioblastoma (GBM)

A clinical trial of Glioblastoma, sponsored by University of Nebraska.

Completed
Registry status
19
Enrollment target
1
Study location

NCT01493219: Completed study of Glioblastoma, sponsored by University of Nebraska.

NCT01493219 is a study of Glioblastoma that has completed, run by University of Nebraska. The registered enrollment target is 19 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01493219, a study of Glioblastoma, has completed, sponsored by University of Nebraska.

COMPLETED
Registry status
19 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is: 1. To learn if (MMP-2, MMP-9 and NGAL) which are substances found in blood and urine associated with tumors, can be used as tumor markers in the management and treatment of glioblastoma. 2. To study the relationship between MMP-2, MMP-9 and NGAL with quality of life and disease symptoms.

Primary Outcome

For each outcome (MMP-2, MMP-9 and MMP-9/NGAL), Pearson's correlation coefficient will be used to examine the association between 1) tissue and urine and 2) tissue and blood. Spearman's correlation will be used in the event that the data are not normally distributed and a suitable transformation is not evident. Due to the anticipated interaction of group with presence of these biomarkers, these analyses will be conducted separately for epilepsy control patients and GBM patients.

Conditions Studied

Glioblastoma

Study Locations (1)

Nebraska

  • University of Nebraska Medical Center - Omaha

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2011-09-20
Est. Completion 2017-09-01
University of Nebraska

407 total trials

What the finished NCT01493219 record still lists

NCT01493219 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (83% lower).

The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 0 interventions.

NCT01493219 reports a single indexed study location in Nebraska.

Frequently Asked Questions

What is clinical trial NCT01493219 about?

NCT01493219 is a clinical study titled "Biomarkers for Prognosis of Glioblastoma (GBM)". The purpose of this study is: 1. To learn if (MMP-2, MMP-9 and NGAL) which are substances found in blood and urine associated with tumors, can be used as tumor markers in the management and treatment of glioblastoma. 2. To study the relationship between MMP-2, MMP-9 and NGAL with quality of life an...

What is the current status of trial NCT01493219?

This trial is currently completed. The enrollment target is 19 participants. The study started on 2011-09-20. Estimated completion is 2017-09-01.

What conditions does trial NCT01493219 study?

This clinical trial studies the following conditions: Glioblastoma.

Who is sponsoring clinical trial NCT01493219?

This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01493219 being conducted?

This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Glioblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01493219's enrollment target sits among peer trials

19 155th of 199 higher than 42 of 199 other Glioblastoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03207464 · 19 participants · Phase 1

    Molecular Imaging of NET Using [C-11]MRB-PET in MS

  • NCT04318717 · 19 participants · Phase 2

    Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

  • NCT05103904 · 19 participants · Phase 2

    Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

  • NCT05904691 · 19 participants · Phase 1

    Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT01493219, the US trial registry maintained by the National Library of Medicine. NCT01493219 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.